Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

se of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The most com
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:6/2/2015)... 2015  University Hospitals (UH) Case Medical ... area to implant a new miniaturized, wireless monitoring ... is the first and only FDA-approved heart failure monitoring device ... used by physicians to manage heart failure., ... implanted in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:6/2/2015)... 2, 2015   PDI , a leader ... a series of corporate commitments designed to educate ... the threat of antimicrobial-resistant microorganisms as part of ... Disease Control and Prevention (CDC) and in support ... Antibiotic-Resistant Bacteria. Along with other key ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced the ... Global Strategic Business Report" report to their offering. ... Canada , Japan , ... Latin America , and Rest of World. ... through 2020. Also, a seven-year historic analysis is provided for ...
Breaking Medicine Technology:UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 2UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 3PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3
(Date:6/2/2015)... 02, 2015 The Down Syndrome Association ... from the hit show Glee as the keynote speaker ... in Pleasant Prairie, WI. The event aims to raise ... Racine, Kenosha, and Walworth counties. , ... us for this important event," says Dawn Nuoffer, DSAW ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... replacement lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is now underway ... to court documents, opening statements were presented on ... laser etchings on the Profemur hip replacement made ... it to snap just three years after it ...
(Date:6/2/2015)... France, and Dallas, TX, USA (PRWEB) June 02, 2015 ... innovative nano and microsystems, is deploying its growth strategy ... applications, focusing on BioMEMS: “In Yole Développement’s May 2015 ... the BioMEMS market will grow sharply and reach $6.6B ... & Sensors at Yole Développement . , The ...
(Date:6/2/2015)... June 02, 2015 ANT Wireless, proven ... market entry of two new products implementing the ANT+ ... announce new wireless interoperability in their bike trainer products, ... cyclists. Tacx has implemented the FE-C device profile in ... well as its new indoor training software, while Kinomap ...
(Date:6/2/2015)... 2015 Acara Partners has seen a spike ... to mobile devices, as is now required by recent Google ... as well as several new clients in the medical aesthetics ... for them to meet Google’s new requirements,” commented Fran Acunzo, ... our clients in education, non-profits, and the business world.” ...
Breaking Medicine News(10 mins):Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:Acara Partners Expands Website and Digital Offerings 2
... A unique, intergenerational program developed by OASIS to ... will be expanded to eight cities during the next ... Foundation, Inc.Active Generations promotes physical activity and healthy eating ... reaches children in grades 3 to 5 in after-school ...
... and GAITHERSBURG, Md., Feb. 25 (CHI,s ... systems biology company focused on identifying molecular ... novel therapeutics, molecular diagnostics and patient-specific therapies, ... partnership agreement with Gene Logic, an Ocimum ...
... Each Sunday throughout March, Sharing Miracles, a ... and inspirational stories of real patients, will feature Hall-of-Famer ... Connecticut men,s basketball team. Sharing Miracles ... United States. An NCAA Division I coach for 37 ...
... (HA)ANDOVER, Mass., Feb. 25 Smith & Nephew,s (NYSE: ... announced the launch of the OSTEORAPTOR Anchor for repair ... at the American Academy of Orthopaedic Surgeons Annual Meeting ... will perform an estimated 15,000 labral repair procedures in ...
... Americans live without dental insurance and as challenging economic ... become increasingly important. With the support of customers ... program is helping these clinics provide families the dental ... visits since its inception. The Tom,s of Maine Dental ...
... in developing countries PITTSBURGH, Feb. 25 Mylan ... that Matrix Laboratories Limited, its India-based subsidiary in ... the first and only World Health Organization (WHO) ... version of this product is heat-stable and affordable, ...
Cached Medicine News:Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 2Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 2Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 3Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 4Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 5Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 6Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 7Health News:'Sharing Miracles' Television Program to Feature UConn Huskies Basketball Coach Jim Calhoun 8Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 2Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 3Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 4Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 3Health News:Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor 2
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... involved in the control of the growth ... which synthesize and secrete male and female ... FSH is controlled by these sex hormones ... FSH Quantitative Test Kit is based on ...
... Our Class II Direct to High Res SSP kits ... a single tray. Locus specific typing on a single ... , Straight from genomic DNA to high resolution ... Allele level typing with a single tray , Unique ...
... to High Res SSP kits provide high resolution typing ... specific typing on a single tray reduces QC and ... genomic DNA to high resolution results, no need for ... a single tray , Unique reaction pattern for most ...
Medicine Products: